CN105377857B - 新颖氮杂苯并咪唑衍生物 - Google Patents

新颖氮杂苯并咪唑衍生物 Download PDF

Info

Publication number
CN105377857B
CN105377857B CN201480040799.5A CN201480040799A CN105377857B CN 105377857 B CN105377857 B CN 105377857B CN 201480040799 A CN201480040799 A CN 201480040799A CN 105377857 B CN105377857 B CN 105377857B
Authority
CN
China
Prior art keywords
pyridin
chloro
furan
yloxy
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480040799.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105377857A (zh
Inventor
F·希梅尔斯巴克
E·朗科普夫
H·瓦格纳
N·雷德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN105377857A publication Critical patent/CN105377857A/zh
Application granted granted Critical
Publication of CN105377857B publication Critical patent/CN105377857B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480040799.5A 2013-07-17 2014-07-14 新颖氮杂苯并咪唑衍生物 Active CN105377857B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13176929.1 2013-07-17
EP13176929 2013-07-17
PCT/EP2014/065004 WO2015007669A1 (en) 2013-07-17 2014-07-14 New azabenzimidazole derivatives

Publications (2)

Publication Number Publication Date
CN105377857A CN105377857A (zh) 2016-03-02
CN105377857B true CN105377857B (zh) 2018-04-10

Family

ID=48790302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480040799.5A Active CN105377857B (zh) 2013-07-17 2014-07-14 新颖氮杂苯并咪唑衍生物

Country Status (20)

Country Link
US (1) US9492436B2 (cg-RX-API-DMAC7.html)
EP (1) EP3022210B1 (cg-RX-API-DMAC7.html)
JP (1) JP6491656B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160033749A (cg-RX-API-DMAC7.html)
CN (1) CN105377857B (cg-RX-API-DMAC7.html)
AR (1) AR096936A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014292236B2 (cg-RX-API-DMAC7.html)
CA (1) CA2918401A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016000026A1 (cg-RX-API-DMAC7.html)
DK (1) DK3022210T3 (cg-RX-API-DMAC7.html)
EA (1) EA032195B1 (cg-RX-API-DMAC7.html)
ES (1) ES2669543T3 (cg-RX-API-DMAC7.html)
HU (1) HUE038261T2 (cg-RX-API-DMAC7.html)
MX (1) MX359040B (cg-RX-API-DMAC7.html)
PH (1) PH12016500092B1 (cg-RX-API-DMAC7.html)
PL (1) PL3022210T3 (cg-RX-API-DMAC7.html)
TR (1) TR201806860T4 (cg-RX-API-DMAC7.html)
TW (1) TW201546076A (cg-RX-API-DMAC7.html)
UY (1) UY35668A (cg-RX-API-DMAC7.html)
WO (1) WO2015007669A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3180338B1 (en) * 2014-08-11 2018-05-09 Boehringer Ingelheim International GmbH Azabenzimidazole derivatives as amp protein kinase agonistes
CN107108605A (zh) 2014-08-27 2017-08-29 盐野义制药株式会社 具有ampk活化作用的氮杂吲哚衍生物
CN107108521A (zh) 2014-10-28 2017-08-29 盐野义制药株式会社 具有ampk活化作用的杂环衍生物
US10053471B2 (en) * 2015-01-16 2018-08-21 Boehringer Ingelheim International Gmbh Azabenzimidazole derivatives
WO2017146186A1 (ja) 2016-02-26 2017-08-31 塩野義製薬株式会社 Ampk活性化作用を有する5-フェニルアザインドール誘導体
EP3459949A4 (en) * 2016-05-20 2020-04-08 Shionogi & Co., Ltd 5-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE WITH AMPK ACTIVATION EFFECT
JP2022508751A (ja) * 2018-10-15 2022-01-19 ゲロ ディスカバリー リミテッド ライアビリティ カンパニー Pfkfb3阻害剤とその使用
UY38941A (es) 2019-11-11 2021-06-30 Pi Industries Ltd Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2022052958A1 (en) 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008895A1 (en) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for the treatment of diabetes and related disorders
WO2012116145A1 (en) * 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2014031468A1 (en) * 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014031515A1 (en) * 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014069426A1 (ja) * 2012-10-31 2014-05-08 塩野義製薬株式会社 Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101889993B1 (ko) 2010-09-10 2018-08-20 시오노기세야쿠 가부시키가이샤 Ampk 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008895A1 (en) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for the treatment of diabetes and related disorders
WO2012116145A1 (en) * 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2014031468A1 (en) * 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014031515A1 (en) * 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014069426A1 (ja) * 2012-10-31 2014-05-08 塩野義製薬株式会社 Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体

Also Published As

Publication number Publication date
AR096936A1 (es) 2016-02-10
CA2918401A1 (en) 2015-01-22
TW201546076A (zh) 2015-12-16
TR201806860T4 (tr) 2018-06-21
AU2014292236A1 (en) 2016-01-21
MX359040B (es) 2018-09-13
UY35668A (es) 2015-01-30
CL2016000026A1 (es) 2016-08-12
HUE038261T2 (hu) 2018-10-29
US9492436B2 (en) 2016-11-15
EA201600113A1 (ru) 2016-07-29
MX2016000547A (es) 2016-04-20
KR20160033749A (ko) 2016-03-28
JP2016527223A (ja) 2016-09-08
DK3022210T3 (en) 2018-06-06
US20150025065A1 (en) 2015-01-22
PH12016500092B1 (en) 2019-04-12
PL3022210T3 (pl) 2018-08-31
CN105377857A (zh) 2016-03-02
ES2669543T3 (es) 2018-05-28
EA032195B1 (ru) 2019-04-30
EP3022210A1 (en) 2016-05-25
PH12016500092A1 (en) 2016-04-18
WO2015007669A1 (en) 2015-01-22
AU2014292236B2 (en) 2018-11-08
JP6491656B2 (ja) 2019-03-27
EP3022210B1 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
JP6491656B2 (ja) 新規アザベンズイミダゾール誘導体
AU2011256444B2 (en) Spiro isoxazoline compounds as SSTR5 antagonists
JP6588966B2 (ja) Ampタンパク質キナーゼ作動薬としてのアザベンゾイミダゾール誘導体
CN110177773B (zh) 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
EA022064B1 (ru) Гетариламинонафтиридины в качестве ингибиторов атф-связывающих белков
CN110088089A (zh) 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
US8822471B2 (en) Compounds, pharmaceutical compositions and uses thereof
JP6474804B2 (ja) アザベンゾイミダゾール誘導体
TW201831476A (zh) 吡啶并〔3,4-d〕嘧啶衍生物及其藥學上所容許之鹽
JP6612881B2 (ja) 新規なアザベンゾイミダゾール誘導体
JP6136032B2 (ja) 新規な2,3−ジヒドロ−フロ[2,3−c]ピリジン、Gタンパク質共役受容体GPR119のモジュレーターとしてのそれらの使用、及びそれらを含む医薬組成物
JP4711228B2 (ja) 複素環を有する新規縮合多環式化合物及びその医薬用途
JP6119081B2 (ja) Gpr119に対するフロ[2,3−c]ピリジン活性物質
US20150225390A1 (en) N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant